Technology/ Title:Development of Therapeutic Antibodies for Multiple-Drug Resistant Bacteria

Summary of Invention
To develop therapeutic antibodies against multiple-drug resistant bacteria, the binding abilities of the antibodies against the standard strains and clinical MDR strains of Klebsiella pneumoniae were analyzed. The anti-bacterial activity of the antibodies were also examined by the in vitro functional assays, including the antibody-induced bacterial agglutination, complement-mediated cytotoxicity, and antibody-mediated opsonophagocytosis. For its in vivo anti-bacterial efficacy, the mAb was evaluated in the KP-infected mouse model. The in vivo pilot pharmacokinetics has been analyzed.

Advantages when compared to the existing technologies
1. Fully human mAb, has longer half-life and low immunogenesity.
2. Target bacterial membrane protein inhibition attachment.
3. Target bacterial membrane protein activated CDC and OPK activity.